SMYD2 and cerebral infarction: ML-385 partially reversed the neuroprotective effect of Smyd-2 knockout in the CIR-created hippocampus lesions, characterized by the significantly increased volume of cerebral infarction, more obvious motor impairment, more outstanding cognitive dysfunction, and more heavy ferrous iron accumulation in the hippocampus.